|
Volumn 77, Issue 1-2, 2001, Pages 77-86
|
Possibility of the reversal of multidrug resistance and the avoidance of side effects by liposomes modified with MRK-16, a monoclonal antibody to P-glycoprotein
|
Author keywords
Cancer chemotherapy; Liposome; Multidrug resistance; P Glycoprotein; Side effect
|
Indexed keywords
DOXORUBICIN;
GLYCOPROTEIN P;
IMMUNOGLOBULIN G2A;
IMMUNOLIPOSOME;
MONOCLONAL ANTIBODY MRK 16;
VERAPAMIL;
VINCRISTINE;
ANTIGEN BINDING;
ARTICLE;
CANCER CHEMOTHERAPY;
CELL LINE;
CONTROLLED STUDY;
CYTOTOXICITY;
DRUG EFFECT;
DRUG EFFICACY;
DRUG UPTAKE;
ENCAPSULATION;
HUMAN;
HUMAN CELL;
INTERMETHOD COMPARISON;
MULTIDRUG RESISTANCE;
MYELOID LEUKEMIA;
PRIORITY JOURNAL;
SIDE EFFECT;
ANTIBODIES, MONOCLONAL;
ANTINEOPLASTIC AGENTS;
DRUG RESISTANCE, MULTIPLE;
DRUG RESISTANCE, NEOPLASM;
HUMANS;
LIPOSOMES;
P-GLYCOPROTEIN;
TUMOR CELLS, CULTURED;
VINCRISTINE;
|
EID: 0035834268
PISSN: 01683659
EISSN: None
Source Type: Journal
DOI: 10.1016/S0168-3659(01)00460-6 Document Type: Article |
Times cited : (52)
|
References (26)
|